Lupin sells Japanese business Kyowa for enterprise value of Rs 3,702.4 crore
Lupin, India’s third-largest drugmaker on November 11 said it has entered into a definitive agreement for the sale of its entire stake in its Japanese subsidiary Kyowa Pharmaceutical Industry Co to Japan-based private equity firm Unison for an enterprise value of Rs 3,702.4 crore. Lupin will get net proceeds of $300 million from the sale, which will be used to pare debt and invest in core markets of the US and India. Under the terms of the agreement, Lupin’s subsidiary Nanomi B.V. will divest its entire stake (99.82 percent) in…
Read More